Reducing light sensitivity after photodynamic therapy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2011-006012-31-DK

Enrollment

Registered

2012-01-17

Start date

2012-02-06

Completion date

Unknown

Last updated

2016-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sun damage skin MedDRA version: 14.1 Level: LLT Classification code 10063071 Term: Solar elastosis System Organ Class: 10040785 - Skin and subcutaneous tissue disorders

Interventions

Trade Name: Metvix Product Name: Metvix Product Code: 32850 Pharmaceutical Form: Cream

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: sun damage skin above age of 18 years Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 10 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 5

Exclusion criteria

Exclusion criteria: immunosuppresion pregnancy porphyria allergy to metvix

Design outcomes

Primary

Measure	Time frame
Main Objective: Reducing light sensitivity after photodynamic therapy using sun protection factors;Secondary Objective: PpIX fluorescence and pain during therapy;Primary end point(s): skin redness after treatment;Timepoint(s) of evaluation of this end point: 1-2 days after treatment	—

Secondary

Measure	Time frame
Secondary end point(s): Ppx fluorescence pain;Timepoint(s) of evaluation of this end point: during and 1-2 days after treatment	—

Countries

Denmark

Contacts

Public ContactDepartment of Dermatology

Bispebjerg Hospital

hwul0001@bbh.regionh.dk004535313156

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026